TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Post-burn scar characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in urine protein to creatinine ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in FENa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in total body water (TBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retention rate of participants at all five intervention sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of eligible referrals that consent to participate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of missing data across outcome assessments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dyspnea Index (DI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with treatment-emergent suicidal ideation and behavior through assessment of Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in exercise capacity (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-reported health status (KCCQ-12)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient-reported quality of life (EuroQol-5d)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in adherence to the Mediterranean Diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participant knowledge of Multiple Myeloma
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of seroconversion determined using Hemagglutination-Inhibition assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With a Suicide Attempt in the Past Three Months
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Active Ideation in Past Week at 3-month Follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate/major aortic regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of PCR Confirmed RSV-associated LRTD With at Least 3 Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of PCR Confirmed RSV-associated LRTD With at Least 2 Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Prediction accuracy of muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Philadelphia Naming Test short-form accuracy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: biochemical analyzes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval from first dose to evidence of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Width of Keratinized Mucosa (KM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant Stability (ISQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UK Prospective Diabetes Study risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed serum (peak) drug concentration (Cmax) of brazikumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under serum concentration-time curve from zero to infinity (AUCinf) of brazikumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve from zero to the last quantifiable concentration (AUClast) of brazikumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial area under the serum concentration-time curve from time zero to 28 days postdose (AUC0-28d) of brazikumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and prevalence of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-perceived, goal-related performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-Rated Wrist Evaluation (PRWE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional results with different Intraocular lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity with different Intraocular lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Microbiome flora number of organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Microbiome flora percentage distribution of organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food intake at subsequent meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the total number of hairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Early Neurological Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: POGO SCORE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of blood lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of salivary cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of salivary interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival Rate (%) at 24 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in Pain on the Visual Analog Pain (VAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in scores on a cognitive assessment Double Trouble
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in scores on a cognitive assessment Feature Match
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in scores on a cognitive assessment Grammatical Reasoning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in scores on a cognitive assessment Digit Span
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety-related complications and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Gastroesophageal Reflux symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lowback pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle architecture 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in hsTnT from preoperative baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Solicited Local and Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs), Unsolicited Adverse Events Associated With New Onset of Chronic Disease (NOCD) or Medically Attended Adverse Events (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients experiencing at least one relevant adverse event related to ExOlin® (mandatory phases)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients experiencing at least one relevant adverse event related to ExOlin® (whole duration of study)
Endpoint domain: Adverse events/effects
Primary endpoint: average number of minutes per day per participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: average number of sessions per day per participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Performance at the 6' step-up test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance at the 6' walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from AF
Endpoint domain: Adverse events/effects
Primary endpoint: freedom from AF/AT/AFL
Endpoint domain: Adverse events/effects
Primary endpoint: freedom from Device/Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Working memory ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in activity of rheumatoid arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Kujala Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 36-Item Short Form Health Survey Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The Lysholm Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: International Knee Documentation Committee Subjective Knee Evaluation Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in swim skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent perception and satisfaction with progress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Video view frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Tai Chi
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chest x-ray or CT chest image
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in symptomatic or radiographic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of knowledge assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Understanding Health Information Well Enough to Know What to do
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Having Sufficient Information to Manage my Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SCORAD (Scoring of Atopic Dermatitis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS (Numeric rating scale for itch)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pain level in response to stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic myofascial pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath spectra comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adverse events / toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Time-course changes in GEH200521 (18F) Injection uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall scan time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of re-irradiation
Endpoint domain: Adverse events/effects
Primary endpoint: Rule-out of cardiac origin of chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility of BOOST Box Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of BOOST Box Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in postprandial levels of methylglyoxal in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurofeedback Training Success
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concordance in HRD status identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of ONC206
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Kidney Failure (AKI) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to task failure (Tlim)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in continuous glucose monitoring time in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness-associated ALK SNP Genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk associated CYP4503A SNP Genotypes
Endpoint domain: Adverse events/effects
Primary endpoint: Memory Task Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory Task Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events (AEs) and adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Residual biotinidase Enzymatic Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Sintomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minute Walk Test Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sperm retrieval rate at mTESE biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: change in insulin resistance index (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of inflammatory indicators after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in renal bleeding after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes of renal-function after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain score after surgery
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of pneumothorax and hydrothorax
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ureteral stone street
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptance of the VR system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of thickening fraction in predicting weaning outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of 131I-omburtamab
Endpoint domain: Adverse events/effects
Primary endpoint: AUCt of CKD-386
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-386
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of reoperation on the aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decrease area of wound healing due to Diabetic Foot Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of depth of ulcer involve the deep fascia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amputation Rate
Endpoint domain: Mortality/survival
Primary endpoint: Diabetic Foot Ulcer relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder stress reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of fractional anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measure of mean diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measure of functional MRI cortical activations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in SCORing Atopic Dermatitis (SCORAD) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Accuracy of Belle AI Image References
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on Economic Burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Completion Rate of 2-Week Prehabilitation Program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant Safety During the 2-Week Program
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of the Program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: soft tissue prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of study eyes with a ≥15-letter improvement in BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medically Treated Falls
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation of respiratory support at 32 weeks corrected gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Discontinuation of respiratory support at 33 weeks corrected gestational age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with positive index test result among participants with tuberculosis (TB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with negative index test result among participants without tuberculosis (TB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Imagined Interactions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from Baseline Capacity to Adapt
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Caregiver Capacity to Appraise Demands
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence rate of allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: HPV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pregnancy Stress Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FMS™ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Agreement Rate (OAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TB disease free survival at 12 months post-randomization
Endpoint domain: Mortality/survival
Primary endpoint: TB disease free survival at 24 months post randomization
Endpoint domain: Mortality/survival
Primary endpoint: Cerebrospinal fluid concentration of anti-infective drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stenosis degree of calf artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to peak glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of Breztri aerosphereTM
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events occurring after IP administration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of confirmed first infections with Pf
Endpoint domain: Adverse events/effects
Primary endpoint: Change in affected arm movement control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in use of affected arm in functional activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in habitual arm activity on the affected side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxygenation saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in cardiac rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of Ribociclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EuroQoL (quality of life) Current Health Assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Outpatient visits for gout treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in the Parkinson's Disease Related Pattern (PDRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Parkinson's Disease Cognitive Pattern (PDCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events related to the medication washout
Endpoint domain: Adverse events/effects
Primary endpoint: mortality rates for VLBW infants
Endpoint domain: Mortality/survival